文献速递妇科

子宫肌瘤MED12突变:预测促性腺激素释放激素激动剂治疗后的体积缩小

MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
PubMed 文献 · Am J Obstet Gynecol · 2022-09-20

研究分析168例子宫肌瘤手术标本的MED12外显子2突变,其中41例术前接受亮丙瑞林3.75mg每月皮下注射3个月。携带MED12外显子2突变的肌瘤经促性腺激素释放激素激动剂治疗后体积缩小更小(P<.001),且T2加权磁共振信号更低;基于磁共振信号的分类可无创预测MED12突变状态。

要点

  • MED12外显子2突变者经促性腺激素释放激素激动剂治疗后肌瘤体积缩小更小(P<.001)。
  • MED12外显子2突变肌瘤在T2加权磁共振上信号强度低于野生型。
  • 新磁共振分类中低信号组MED12外显子2突变更常见,中间信号组突变与野生型比例接近。

核心结论

  • MED12突变状态可作为预测促性腺激素释放激素激动剂对子宫肌瘤缩小效果的候选标志物。
  • 磁共振表现可用于无创判断MED12突变状态,以筛选最可能从促性腺激素释放激素激动剂治疗中获益的患者。

研究设计与样本

  • 研究于2005年至2021年在横滨市立大学医院手术(子宫切除或肌瘤剔除)获取168例患者大于5cm的子宫肌瘤标本。
  • 评估MED12外显子2突变及促红细胞生成素表达与磁共振测量的肌瘤体积缩小的关系。
  • 41例患者术前接受亮丙瑞林醋酸盐3.75mg每月皮下注射3个月,治疗前后行非增强磁共振检查以分析体积缩小率。
  • 开发基于T2加权磁共振信号的肌瘤分类系统,以无创预测MED12突变的存在与否。

主要发现

  • 携带MED12外显子2突变的患者经促性腺激素释放激素激动剂治疗后肌瘤体积缩小更小(P<.001,曼-惠特尼U检验)。
  • MED12外显子2突变肌瘤的T2加权磁共振信号强度低于表达野生型MED12外显子2的肌瘤。
  • 新磁共振分类系统中,低信号组MED12外显子2突变频率高于高信号组,中间信号组突变型与野生型比例接近。
  • 低信号组促红细胞生成素表达水平显著低于高信号组(P<.001,克鲁斯卡尔-沃利斯检验及Dunn事后分析)。

临床怎么用

  • 作者认为MED12突变状态可作为预测促性腺激素释放激素激动剂缩小子宫肌瘤效果的候选标志物。
  • 作者认为磁共振表现可作为无创策略判断MED12突变状态,以筛选最可能从促性腺激素释放激素激动剂治疗中获益的患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gonadotropin-releasing hormone agonists are used to treat premenopausal uterine leiomyomas; however, leiomyoma volume reduction is not always achieved. The reduction rate after this treatment varies for each leiomyoma, even in the same patient. Therefore, an effective method for predicting uterine leiomyoma volume reduction is required to reduce the adverse hypoestrogenic effects and drug-related economic burden related to gonadotropin-releasing hormone agonists. OBJECTIVE: This study aimed to determine the predictive use of MED12 mutations for evaluating the effect of gonadotropin-releasing hormone agonist treatment concerning reducing uterine leiomyoma volume and to predict the MED12 mutation status based on the findings of magnetic resonance imaging performed before treatment. STUDY DESIGN: MED12 exon 2 mutation and erythropoietin expression in uterine leiomyomas were evaluated concerning volume reduction, as measured using magnetic resonance imaging. We developed a system for classifying leiomyomas according to T2-weighted magnetic resonance imaging signals to noninvasively predict the presence or absence of MED12 mutations in leiomyomas. Leiomyoma samples (>5 cm) were obtained from 168 patients during surgery (hysterectomy or myomectomy) between 2005 and 2021 at Yokohama City University Hospital. To analyze the rate of leiomyoma volume reduction, 41 patients had been preoperatively administered the gonadotropin-releasing hormone agonist (leuprorelin acetate 3.75 mg, monthly subcutaneous injection) for 3 months; magnetic resonance imaging was performed before and after treatment without contrast material. RESULTS: Patients with MED12 exon 2 mutations had smaller volume reduction after treatment with the gonadotropin-releasing hormone agonist (P<.001, Mann-Whitney U test) and displayed lower signal intensity on T2-weighted images than those with leiomyomas expressing wild-type MED12 exon 2. The newly proposed magnetic resonance imaging-based classification system showed that MED12 exon 2 mutations were more frequent in the low-signal group than in the high-signal group, with nearly equal proportions of mutated and wild-type MED12 exon 2 leiomyomas noted in the intermediate group. The low-signal group had significantly lower erythropoietin expression levels than the high-signal group (P<.001, Kruskal-Wallis test with the Dunn posthoc analysis). CONCLUSION: MED12 mutation status can be a candidate marker for predicting the effect of gonadotropin-releasing hormone agonists on uterine leiomyoma reduction. Magnetic resonance imaging findings can be used to determine MED12 mutation status as a noninvasive strategy to select patients who will most likely benefit from gonadotropin-releasing hormone agonist treatment.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Nagai K, Asano R, Sekiguchi F, et al. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists. Am J Obstet Gynecol. 2022. PMID: 36150519. doi:10.1016/j.ajog.2022.09.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。